Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Showing 1-25 of 102 citing articles:

Overall survival with [177Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial
Michael S. Hofman, Louise Emmett, Shahneen Sandhu, et al.
The Lancet Oncology (2023) Vol. 25, Iss. 1, pp. 99-107
Closed Access | Times Cited: 84
First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial
Karim Fizazi, Arun Azad, Nobuaki Matsubara, et al.
Nature Medicine (2023) Vol. 30, Iss. 1, pp. 257-264
Open Access | Times Cited: 64
177Lu-PSMA-617 versus a change of androgen receptor pathway inhibitor therapy for taxane-naive patients with progressive metastatic castration-resistant prostate cancer (PSMAfore): a phase 3, randomised, controlled trial
Michael J. Morris, Daniel Castellano, Ken Herrmann, et al.
The Lancet (2024) Vol. 404, Iss. 10459, pp. 1227-1239
Closed Access | Times Cited: 36
Development of PARP inhibitors in advanced prostate cancer
María T. Bourlon, Paola Valdez, Elena Castro
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 21
Management of Patients with Advanced Prostate Cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)
Silke Gillessen, Fabio Turco, Ian D. Davis, et al.
European Urology (2024)
Open Access | Times Cited: 16
Pembrolizumab Plus Docetaxel Versus Docetaxel for Previously Treated Metastatic Castration-Resistant Prostate Cancer: The Randomized, Double-Blind, Phase III KEYNOTE-921 Trial
Daniel P. Petrylak, Raffaele Ratta, Nobuaki Matsubara, et al.
Journal of Clinical Oncology (2025)
Closed Access | Times Cited: 2
Xaluritamig, a STEAP1 × CD3 XmAb 2+1 Immune Therapy for Metastatic Castration-Resistant Prostate Cancer: Results from Dose Exploration in a First-in-Human Study
William K. Kelly, Daniel C. Danila, Chia‐Chi Lin, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 76-89
Open Access | Times Cited: 29
A Phase I Study of Acapatamab, a Half-life Extended, PSMA-Targeting Bispecific T-cell Engager for Metastatic Castration-Resistant Prostate Cancer
Tanya B. Dorff, Lisa G. Horvath, Karen A. Autio, et al.
Clinical Cancer Research (2024) Vol. 30, Iss. 8, pp. 1488-1500
Closed Access | Times Cited: 13
Metastatic Hormone-Sensitive Prostate Cancer and Combination Treatment Outcomes
Maha Hussain, Karim Fizazi, Neal D. Shore, et al.
JAMA Oncology (2024) Vol. 10, Iss. 6, pp. 807-807
Closed Access | Times Cited: 13
Diverse Imaging Methods May Influence Long-Term Oncologic Outcomes in Oligorecurrent Prostate Cancer Patients Treated with Metastasis-Directed Therapy (the PRECISE-MDT Study)
Matteo Bauckneht, Francesco Lanfranchi, Domenico Albano, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 8, pp. 1202-1209
Open Access | Times Cited: 11
Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial
Guilhem Roubaud, Marie Kostine, Ray McDermott, et al.
European Journal of Cancer (2025) Vol. 218, pp. 115293-115293
Closed Access | Times Cited: 1
Impact of stereotactic body radiotherapy after progression in castrate resistant prostate cancer patients undergoing first line abiraterone treatment. A subgroup analysis from ARTO trial (NCT03449719)
Giulio Francolini, Niccolò Bertini, Vanessa Di Cataldo, et al.
Prostate Cancer and Prostatic Diseases (2025)
Closed Access | Times Cited: 1
The current status of prostate cancer treatment and PSMA theranostics
Motohide Uemura, Tadashi Watabe, Seiji Hoshi, et al.
Therapeutic Advances in Medical Oncology (2023) Vol. 15
Open Access | Times Cited: 17
Differences and Common Ground in177Lu-PSMA Radioligand Therapy Practice Patterns: International Survey of 95 Theranostic Centers
Andrea Farolfi, Wesley R. Armstrong, Loïc Djaileb, et al.
Journal of Nuclear Medicine (2024) Vol. 65, Iss. 3, pp. 438-445
Open Access | Times Cited: 8
EORTC 2238 “De-Escalate”: a pragmatic trial to revisit intermittent androgen deprivation therapy in the era of new androgen receptor pathway inhibitors
Guillaume Grisay, Fabio Turco, Saskia Litière, et al.
Frontiers in Oncology (2024) Vol. 14
Open Access | Times Cited: 7
Balancing Hormone Therapy: Mitigating Adverse Effects of Androgen-Deprivation Therapy and Exploring Alternatives in Prostate Cancer Management
Lisa M. Gudenkauf, S. Gray, Brian D. Gonzalez, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7
Nomogram to predict the presence of PSMA-negative but FDG-positive lesion in castration-resistant prostate cancer: a multicenter cohort study
Jian Pan, Tingwei Zhang, Shouzhen Chen, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 6
Intensification Approaches and Treatment Sequencing in Metastatic Castration-resistant Prostate Cancer: A Systematic Review
Edoardo Francini, Neeraj Agarwal, Elena Castro, et al.
European Urology (2024) Vol. 87, Iss. 1, pp. 29-46
Closed Access | Times Cited: 6
Intrapatient Intermetastatic Heterogeneity Determined by Triple-Tracer PET Imaging in mCRPC Patients and Correlation to Survival: The 3TMPO Cohort Study
Frédéric Pouliot, Fred Saad, Étienne Rousseau, et al.
Journal of Nuclear Medicine (2024), pp. jnumed.124.268020-jnumed.124.268020
Closed Access | Times Cited: 6
AMG 509 (Xaluritamig), an Anti-STEAP1 XmAb 2+1 T-cell Redirecting Immune Therapy with Avidity-Dependent Activity against Prostate Cancer
Olivier Nolan-Stevaux, Cong Li, Lingming Liang, et al.
Cancer Discovery (2023) Vol. 14, Iss. 1, pp. 90-103
Closed Access | Times Cited: 15
Second-line treatment options in metastatic castration-resistant prostate cancer after progression on first-line androgen-receptor targeting therapies: A systematic review and Bayesian network analysis
Xingyu Xiong, Shiyu Zhang, Weitao Zheng, et al.
Critical Reviews in Oncology/Hematology (2024) Vol. 196, pp. 104286-104286
Closed Access | Times Cited: 5
Emerging Theranostics for Prostate Cancer and a Model of Prostate-specific Membrane Antigen Therapy
Kerry Jewell, Michael S. Hofman, Jeremy S. L. Ong, et al.
Radiology (2024) Vol. 311, Iss. 1
Closed Access | Times Cited: 4
Radiographic Progression Without Corresponding Prostate-specific Antigen Progression in Patients with Metastatic Castration-sensitive Prostate Cancer Receiving Apalutamide: Secondary Analysis of the TITAN Trial
Wataru Fukuokaya, Takafumi Yanagisawa, Keiichiro Mori, et al.
European Urology Oncology (2024)
Closed Access | Times Cited: 4
Prognostic and Predictive Role of SPOP Mutations in Prostate Cancer: A Systematic Review and Meta-analysis
Martino Pedrani, Giuseppe Salfi, Sara Merler, et al.
European Urology Oncology (2024) Vol. 7, Iss. 6, pp. 1199-1215
Open Access | Times Cited: 4
PARP inhibitors in prostate cancers, is it time for combinations?
Diego Teyssonneau, Charles Dariane, Éric Barret, et al.
Therapeutic Advances in Medical Oncology (2024) Vol. 16
Open Access | Times Cited: 4
Page 1 - Next Page

Scroll to top